KH607 / Chengdu Kanghong Pharma - LARVOL DELTA

A Study of KH607 as Monotherpy in Adults Participants With Major Depressive Disorder (clinicaltrials.gov) - P3 | N=232 | Not yet recruiting | Sponsor: Chengdu Kanghong Pharmaceutical Group Co., Ltd.

New P3 trial • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

A Phase 2 Study to Evaluate Efficacy and Safety of KH607 Tablets in Adult Participents With Major Depressive Disorder (clinicaltrials.gov) - P2 | N=126 | Completed | Sponsor: Chengdu Kanghong Pharmaceutical Group Co., Ltd. | Not yet recruiting ➔ Completed

Trial completion • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

A Phase 2 Study to Evaluate Efficacy and Safety of KH607 Tablets in Woman With Postpartum Depression (clinicaltrials.gov) - P2 | N=72 | Completed | Sponsor: Chengdu Kanghong Pharmaceutical Group Co., Ltd. | Not yet recruiting ➔ Completed | Trial completion date: Apr 2027 ➔ Apr 2026 | Trial primary completion date: Jan 2027 ➔ Apr 2026

Trial completion • Trial completion date • Trial primary completion date • CNS Disorders • Depression • Mood Disorders • Postpartum Depression • Psychiatry

Compare the Efficacy and Safety of KH607 Tablets Versus Vortioxetine Hydrobromide Tablets in Adult Patients With Major Depressive Disorder (clinicaltrials.gov) - P3 | N=326 | Not yet recruiting | Sponsor: Chengdu Kanghong Pharmaceutical Group Co., Ltd.

New P3 trial • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

A Phase 2 Study to Evaluate Efficacy and Safety of KH607 Tablets in Adult Participents With Major Depressive Disorder (clinicaltrials.gov) - P2 | N=120 | Completed | Sponsor: Chengdu Kanghong Pharmaceutical Group Co., Ltd. | Recruiting ➔ Completed

Trial completion • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

A Study to Evaluate the Effect of Food on the Pharmacokinetic Characteristics and Safety Profile of KH607 in Healthy Chinese Participants (clinicaltrials.gov) - P1 | N=16 | Not yet recruiting | Sponsor: Chengdu Kanghong Pharmaceutical Group Co., Ltd.

New P1 trial

A Phase 2 Study to Evaluate Efficacy and Safety of KH607 Tablets in Woman With Postpartum Depression (clinicaltrials.gov) - P2 | N=72 | Not yet recruiting | Sponsor: Chengdu Kanghong Pharmaceutical Group Co., Ltd.

New P2 trial • CNS Disorders • Depression • Mood Disorders • Postpartum Depression • Psychiatry

A Phase 2 Study to Evaluate Efficacy and Safety of KH607 Tablets in Adult Participents With Major Depressive Disorder (clinicaltrials.gov) - P2 | N=120 | Not yet recruiting | Sponsor: Chengdu Kanghong Pharmaceutical Group Co., Ltd.

New P2 trial • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

The Discovery and Development of KH607 as a Treatment for Postpartum Depression (PPD) and Major Depressive Disorder (MDD) (APA 2025) - "Phase II clinical studies are currently ongoing. We expect that the compound to be developed as a new treatment to address the unmet medical needs for PPD and MDD patients."

CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Postpartum Depression • Psychiatry

Phase 1 Study of KH607 Tablets (clinicaltrials.gov) - P1 | N=88 | Recruiting | Sponsor: Chengdu Kanghong Pharmaceutical Group Co., Ltd.

New P1 trial